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The  complement  serum  proteins  C3  and  C4 and  the  protease  inhibitor  -2  macroglobulin  are  all  members
of  the  C3/-2M  thioester  protein  family,  an  evolutionarily  ancient  and  conserved  family  that  contains  an
intrachain  thioester  bond.  The  chemistry  of the  thioester  bond  is  a key  to  the  function  of  the  thioester
proteins.  All  these  proteins  function  by  covalently  linking  to  their  target  by acyl  transfer  of  the  protein
via  the  thioester  moiety.  We  show  that  the  signature  thioester  bond  can  be  targeted  with  nucleophiles
linked  to a bioreporter  molecule,  site-speciﬁcally  modifying  the  whole,  intact  thioester  protein.  Con-
ditions  were  optimised  to  label  selectively  and  efﬁciently  pull-down  unprocessed  thioester-containing
proteins  from  serum.  We  demonstrated  pull-down  of  full-length  C3,  -2M  and  C4  from  sera  in high salt,
using  a biotinylated  nucleophile  and  streptavidin-coated  resin,  conﬁrmed  by  MALDI-TOF  MS identiﬁca-
tion  of  the  gel  bands.  The  potential  for the  development  of  a quantitative  method  for  measuring  active  C3
in serum  was  investigated  in patient  sera  pre  and  post  operation.  Quantifying  active  C3 in  clinical  assays
using  current  methods  is  difﬁcult.  Methods  based  on  antibody  detection  (e.g. nephelometry)  do  not dis-
tinguish  between  active  C3 and  inactive  breakdown  products.  C3-speciﬁc  haemolytic  assays  can  be  used,
but these  require  use  of  relatively  unstable  reagents.  The  current  work  represents  a  promising  robust,
enzyme-  and  antibody-free  chemical  method  for  detecting  active  thioester  proteins  in blood,  plasma  or
serum.
 ntroduction
The C3 and C4 thioester proteins of the complement pathway
nd the protease inhibitor -2 macroglobulin (-2M) form the ﬁrst
ine of defence of the innate immune system against pathogens. Fol-
owing limited proteolysis, C3 and C4 attach covalently to pathogen
urfaces by acyl transfer via their thioester functionality and this
rreversible attachment is central to pathogen recognition and
learance. -2M interacts with exogenous proteases, and binds
ovalently to them, inhibiting their activity. In contrast to their
rotective effects, inappropriate or excessive activation of C3 is
nvolved in many autoimmune, degenerative and inﬂammatory
iseases. There is therefore great interest in techniques that can
Abbreviations: C3, complement component 3; C3(H2O), C3 with hydrol-
sed thioester; C3(NH2NH2), hydrazine labelled C3; C3(bio), C3 labelled with
iotin–PEG4–hydrazide; C3(N), C3 labelled with nucleophile at thioester bond; fI,
omplement factor I; fH, complement factor H; EACA, epsilon amino caproic acid;
-2M, -2 macroglobulin; PEG-plasma, plasma precipitated by PEG 3350; SA, strep-
avidin; HRP, horseradish peroxidase.
∗ Corresponding author. Tel.: +44 20 88 16 20 82.
E-mail address: joffer@nimr.mrc.ac.uk (J. Offer).
171-2985 © 2011 Elsevier GmbH. 
oi:10.1016/j.imbio.2011.07.021
Open access under CC BY license. © 2011 Elsevier GmbH. 
monitor the concentration of the active forms of these proteins as
potential indicators of disease progression.
The site-speciﬁc labelling of proteins within a complex biologi-
cal mixture like serum or plasma requires chemoselective reaction
of the label with a unique site of a protein under near physio-
logical conditions and in the presence of a vast array of other
biomolecules. Some chemoselective reactions have been harnessed
for activity based labelling, contributing signiﬁcantly to the eluci-
dation of numerous biological processes. Complement protein C3,
as well as other proteins of the C3/-2M thioester protein family
all possess an eponymous thioester bond that bridges the cysteine
and glutamine side chains of the conserved sequence GCGEQ to
form the internal -cysteinyl--glutamyl, ﬁfteen-membered thi-
olactone ring, a distinctive post-translational modiﬁcation of this
class of proteins that makes this family theoretically amenable to
site-speciﬁc labelling (Fig. 1). In almost all cases of activity-based
labelling, a protein activity is targeted by an electrophilic warhead
(Heal et al. 2011), however for the C3/-2M family this situation
is reversed, as the thioester bond is itself the warhead and can
Open access under CC BY license.be targeted with an appropriately reactive nucleophile. Thioester
proteins are present in high concentrations in blood plasma as the
broad-spectrum protease inhibitor -2M (2.0 mg  ml−1) and as C3
(1.2 mg  ml−1) and C4 (∼0.6 mg ml−1) of the complement pathway.
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Fig. 1. Reactivity of the unactivated thioester of complement protein C3. (A) The tick over event of the alternative pathway. C3(H2O) is formed by the slow hydrolysis of C3.
Interaction between factor B and C3(H2O) forms an active C3 convertase complex that can generate more C3b molecules by cleavage of the C3a domain from C3, forming a
positive  feedback loop. C3b has a metastable thioester group that can react rapidly with nucleophiles such as the hydroxyl groups on carbohydrates or amines on proteins. (B)
A  generalised reaction mechanism for the reaction of a nucleophile with the thioester of full-length C3 (tick over event). This gives a route for the modiﬁcation of the whole
C3  protein without activation. The ﬁfteen-membered intramolecular thiolactone ring is the deﬁning feature of the C3/-2M thioester protein family, an evolutionary ancient
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bamily  of proteins that all function by forming covalent linkage of the protein to a t
lutamine side chains with a -cysteinyl--glutamyl bond.
3 is a 190 kDa protein consisting of a 113 kDa -chain, containing
he thioester bond, and a 75 kDa -chain linked by a single disul-
hide bond. In recent years, the crystal structures (Fredslund et al.
006; Janssen et al. 2005, 2006) of intact complement C3 and its
ctivation product C3b (Fig. 1) have revealed the two end points of
he structural transition that takes place when the C3 molecule is
ctivated and cleaved: upon going from C3 to C3b, the C3 domain
ontaining the thioester (TED domain) undergoes a large rearrange-
ent, while the domains surrounding the anaphylotoxin domain
ANA) also change orientation and expose surfaces for interac-
ion with Factor B (fB), Factor I (fI) and its cofactors such as fH.
lthough it has not received the attention of C3, -2M is an impor-
ant serum protein that acts as a broad range protease inhibitor by
hysically trapping proteases and preventing them reaching sub-
trate (Salvesen and Barrett 1980). -2M has a ‘bait’ region with
igh substrate activity for a wide range of proteases. Analogous to
he C3a or ANA domain in C3, cleavage of this bait region causes
 dramatic conformational change. Related thioester containing
roteins are represented across metazoans (Dodds and Law 1998)
nd include the thioester protein (Tep) of Drosophila (Baxter et al.
007).
The intact thioester proteins behave as typical protein thioesters
ith an estimated half-life of hydrolysis of the thioester of intact C3
∼160 h) within the range of a peptide thioester (Davies and Sim
981). Characteristically for thioesters they are much more sus-
eptible to aminolysis than hydrolysis (Yang and Drueckhammer
001) and this observation has been used in many studies to incor-
orate low molecular weight nucleophiles (Law and Dodds 1997).
urthermore, the slow hydrolysis of intact C3 that constitutes the
tick over’ event of the alternative pathway to form C3(H2O) shows
hat the thioester bond is in contact with solvent. C3(H2O) can
orm a convertase C3(H2O)Bb (Fig. 1) like its truncated relative
3b and is a substrate for fI, and although no structure has yet
een reported for C3(H2O) it is assumed to behave similarly to
3b (Bexborn et al. 2008). Cleavage (in this case hydrolysis) of
he thioester bond is enough to cause transition to a C3b-like
tructure. This pathway would therefore seem an ideal route to
ncorporate nucleophiles attached to a bioreporter (as suggested in
igs. 1 and 2A). The thioester bond is a very rare post-translational
odiﬁcation for an extracellular protein and reactive to nucle-
philes so that it can be chemoselectively derivatized. Nevertheless
hemical approaches to labelling and regulating complement have
een largely neglected. When activated by limited proteolysis theia the thioester bond. The thioester moiety is formed by bridging the cysteine and
thioester becomes extremely reactive with a very short serum
lifetime, and will react rapidly with many nucleophiles (Sim and
Law 1985; Sim et al. 1981). Conjugation of C3b to ovalbumin and
other targets (Cretin et al. 2007; Villiers et al. 1999) has been
achieved by adding trypsin to C3 in an excess of the conjugating
agent to take advantage of this activation, although coupling efﬁ-
ciency is low. Radiolabelled methylamine has been incorporated
into serum fractions of many organisms to screen for the pres-
ence of thioester proteins across metazoans (Dodds et al. 1998).
Recently, an ingenious method has been used to label C3 efﬁciently
with larger molecules, C3 is treated with methylamine, and as
the thioester is aminolysed the cysteine side-chain becomes tran-
siently available for derivatization. This promising approach has
been used to conjugate C3 to harness its immunological prop-
erties (Mitchell et al. 2008). We  have previously demonstrated,
that puriﬁed C3 thioester can be directly reacted via the thioester
bond with much larger biomolecules than were used before. How-
ever it was  still difﬁcult to measure the efﬁciency of the reaction,
estimated by indirect methods such as ability to perform the auto-
cleavage reaction (Cole et al. 2009). Attempts at pull-down directly
from sera gave complex product mixtures from post-derivatization
processing. We  considered that it would be worthwhile to reinves-
tigate serum pull-down of full-length derivatized protein with the
knowledge that high salt inhibits formation of C3(N)fHfI (Soames
and Sim 1997). This approach would yield efﬁcient labelling
by pull-down of the intact, derivatized material, directly from
serum.
Our aim is to develop a detection reagent that reacts with
thioester proteins in serum, without need to purify the protein. An
activity-based approach using a nucleophile attached to a reporter
molecule would potentially be able to extract and detect the
active thioester proteins present (Heal et al. 2011). This chemical
approach would accelerate and simplify complement detection by
obviating the need for expensive antibodies and dedicated machin-
ery. More importantly this technique will allow us to directly
quantify active complement C3 or C4 in serum. The pivotal role of
complement in the immune response is reﬂected in the number of
medical conditions correlated with abnormal complement activa-
tion or consumption (Morgan and Harris 2003; Nilsson et al. 2011).
Thioester labelling would also be useful for screening and compar-
ison of thioester proteins from a wide variety of metazoans, but
most importantly for direct longitudinal studies of active C3, C4
levels in different diseases.
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Fig. 2. Chemical labelling of C3 thioester bond. (A) Schematic representation of C3 polypeptide structure and primary activation products. Interchain disulﬁde bonds are
represented by dotted lines, C3a in grey and product sizes are indicated. Protease activation of C3 by C3 convertases followed by a rapid reaction of the activated thioester
to  surrounding nucleophilic groups to form C3b bound nucleophile C3b(N). The labelling of C3 by the direct reaction of nucleophile with the thioester without protease C3a
cleavage gives C3(N). FI and cofactor fH process C3b to iC3b by protease cleavage. The C3(N) conjugate possesses a C3b like structure and can be processed in the same way
(Law  and Dodds, 1997). (B) Temperature dependence of biotin–PEG4–hydrazide labelling of puriﬁed C3. Puriﬁed C3 incubated with biotin–PEG4–hydrazide for 1 h at indicated
temperatures. Samples analysed by 6% SDS-PAGE by Western blots of SA-HRP. (C) SDS-PAGE for comparison of C3(N) processing with fI and fH: C3(NH2NH2) C3(bio), C3(H2O)
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aterials and methods
lood/plasma/serum preparation
Blood was drawn from healthy volunteers and either used
mmediately or the plasma/serum separated and stored at −80 ◦C.
or serum samples the freshly drawn blood was  left at room
emperature for 30 min, cells and resulting clot were pelleted
y centrifugation (2000 × g, 15 min) and the serum stored at
80 ◦C. Plasma was prepared by collecting freshly drawn blood
typically 15 ml)  in centrifugation tubes (Corning, 15 ml)  con-
aining 1.8 mg  sodium EDTA/ml blood (ﬁnal EDTA concentration
bout 5 mM).  Tubes were inverted carefully to mix  the sam-
les and left on ice (10 min) before centrifugation (2000 × g,
0 min). The plasma fraction was retained. Paired plasma sam-
les (pre-operative, POD0 and 48–60 h post-operative, POD3) were
btained from patients enrolled in the Post-Operative Morbid-
ty: Exercise (POM-E) Study [UKCRN ID 8165/ISRCTN 90019424].
ubjects in this observational study were recruited in accordance
ith Local Research Ethics Committee approval and underwent
lective total hip or knee replacement at University College Hos-
ital London. Following informed consent, freshly drawn blood
amples were mixed with heparin (ﬁnal concentration 50 iu/ml
lood) and kept on ice before centrifugation (2000 × g, 10 min
t 4 ◦C). The upper plasma fraction was retained and stored
t −80 ◦C.
uriﬁcation of C3, fH, fIHuman C3 was puriﬁed as previously described (Dodds 1993).
rieﬂy, plasma (typically 7.5 ml)  was precipitated with a half vol. of
5% PEG 3350 (Sigma) in Buffer A (20 mM tris, 50 mM EACA, 5 mM
DTA, 0.02% NaN3, 0.2 mM PMSF, pH 7.5) to give a ﬁnal PEG concen-dialysed in PBS before reaction with fI and fH for 1 h at rt. Processing of C3 detected
tration of 5%. Samples were kept on ice (0 ◦C, 30 min) with gentle
agitation and the resulting precipitate was pelleted by centrifuga-
tion (9500 × g, 20 min, 4 ◦C). PEG precipitated plasma (PEG-plasma)
was  ﬁltered, degassed and anion exchange chromatography was
performed on an Äkta (GE, Uppsala) with a Q-Sepharose column
(20 cm × 1.6 cm diam.), eluting with a NaCl gradient (10 CV, 5–50%
Buffer B, where Buffer B is 1 M NaCl in Buffer A, ﬂow 1 ml/min).
Fractions containing C3, as assessed by SDS-PAGE analysis, were
pooled and diluted with 1 vol of water before puriﬁcation with
higher resolution ion exchange chromatography using a monoQ
column (MonoQ 10/100GL), equilibrated in 90% A, 10% B. Bound
proteins were eluted with a NaCl gradient (20 ml,  10–30% buffer
B, ﬂow 1 ml/min). Purity of the C3 preparation was determined by
SDS-PAGE.
fI and fH were prepared as described by (Sim et al. 1993) and
were generously provided by Dr. Pietro Roversi (Pathology, Oxford
University).
Chemical functionalization of thioester bond
The thioester protein samples (blood/plasma/serum or puriﬁed
C3) (200 l) were diluted with PBS (200 l), mixed with an equal
volume of NaCl (2 M,  400 l) and biotin–PEG4–hydrazide (Celares,
GmbH, Berlin) (250 mM,  16 l) giving a ﬁnal NaCl concentration of
1 M and a probe concentration of 5 mM.  The mixture was  incubated
at 37 ◦C, 42 ◦C, 47 ◦C, 52 ◦C or 57 ◦C for 1 h or 37 ◦C for 24 h. Un-
reacted biotin–PEG4–hydrazide was removed by dialysis against Ca
and Mg-free Dulbecco’s PBS pH 7.4 (5 × 250 ml) at 4 ◦C using Slide-until use. For the preparation of reference proteins: hydrolysed C3
(C3(H2O)) and hydrazine treated C3 (C3(NH2NH2)) were performed
as above with the addition of either H2O or a hydrazine solution
(250 mM,  pH 7) for 1 h at 52 ◦C.
biolog
W
w
a
b
n
P
d
(
(
b
w
b
w
n
ﬁ
P
r
a
w
(
w
(
t
f
r
w
P
t
r
m
C
(
n
w
b
q
R
B
B
B
p
a
c
Q
l
C
s
1
b
d
e
g
m
u
t
T
t
wL. Holm et al. / Immuno
estern blot
Thioester-containing proteins from blood/serum or plasma
ere labelled by incubation with biotinylated probes as described
bove. Samples were boiled for 7 min  in 2 times SDS loading
uffer with or without 5% -mercaptoethanol, for reducing or
on-reducing conditions respectively. Novex® Sharp Pre-Stained
rotein Standard (Invitrogen) was used as molecular weight stan-
ard. Following SDS-6% PAGE using the procedure of Laemmli
1970) the proteins were blotted onto nitrocellulose membrane
0.45 m,  Thermo Scientiﬁc). The membrane was blocked with 3%
ovine serum albumin (BSA) in PBS for 1 h at rt and washed 3 times
ith PBST (PBS with 0.05% Tween 20). The membrane was incu-
ated with SA-HRP (Pierce) 1:50,000 in 1% BSA in PBS (1 h, rt),
ashed 5 times with PBST, rinsed (PBS), developed using SuperSig-
alWestPico (Pierce), and detected by exposure to CL-XposureTM
lm (ThermoScientiﬁc).
ull-down of biotinylated proteins from blood, serum or plasma
Sufﬁcient slurry of Pierce High Capacity Streptavidin–Agarose
esin (Pierce, IL) to give approximately 75 l settled resin in
 microtube (1.5 ml)  was prepared for each sample. Resin was
ashed 3–5 times in PBS (400 l) followed by centrifugation
500 × g, 1 min). Blood, plasma, serum or puriﬁed C3 derivatised
ith biotin–PEG4–hydrazide (500 l), was mixed with 10% SDS
50 l) to give a ﬁnal SDS concentration of 0.9%. The mix  was added
o the washed SA resin and incubated at rt with end-over rotation
or 2 h. The slurry was centrifuged (500 × g, 1 min.), supernatant
emoved and the resin re-suspended in PBS (200 l). The slurry
as transferred to a spin column (spin cups-cellulose acetate ﬁlter,
ierce) washed 5 times with PBS (400 l) each followed by cen-
rifugation (1000 × g, 3 min) and removing the ﬂow through. The
esin was ﬁnally re-suspended in 2% SDS (400 l), transferred to a
icrotube (1.5 ml), allowed to settle and the supernatant decanted.
aptured proteins were eluted from the resin in Laemmli buffer
40–50 l) (62.5 mM Tris, 25% glycerol, 2% SDS, 0.01% Bromophe-
ol Blue) by boiling for 7 min. Immediately after boiling the slurry
as centrifuged (1500 × g, 1 min) and the supernatant analysed
y SDS-6% PAGE or Nu-PAGE 4–12% gradient gel (Invitrogen) for
uantiﬁcation. Gel staining was performed using Coomassie blue
-250 or for quantiﬁcation LumeteinTM protein gel stain (Biotium).
and intensities were measured on a STORM 860 (Amersham
iosciences) and quantiﬁed using ImageQuantile TL (Amersham
iosciences). A paired-sample t test was performed on patient sam-
les. Patient C3 concentrations were estimated from C3 reference
dded as an internal gel standard and the C3 calibration standard
urve.
uantiﬁcation of C3 in plasma
Paired patient plasma samples (POD0 and POD3) and C3 were
abelled with biotin–PEG4–hydrazide as described above. The
3(bio) concentration was determined from A280 and a 2× dilution
eries of C3(bio) in PBS was prepared starting from 1.25 M (500 l,
17.5 g). 500 l of the prepared C3(bio) dilutions and 500 l of
iotin–PEG4–hydrazide labelled plasma were subjected to SA-pull
own (as described above) and analysed on Nu-PAGE 4–12% gradi-
nt gel (Invitrogen). The gels were stained in LumeteinTM protein
el stain (Biotium). Band intensities of pull-down C3 proteins were
easured on a STORM 860 (Amersham Biosciences) and quantiﬁed
sing ImageQuantile TL (Amersham Biosciences). A paired sample
-test was performed on band intensities for the patient samples.
he difference between POD0 and POD3 was compared using the
-test in excel (one-tailed, type 1 paired). Patient C3 concentrations
ere estimated from a C3 reference added as an internal gel stan-y 217 (2012) 256– 264 259
dard and the C3(bio) calibration standard curve. Each paired sample
was  normalised with respect to the POD0 sample and the aver-
age change in POD3 was calculated and displayed with standard
deviation.
Peptide mass ﬁngerprinting
Protein bands were excised from the Coomassie stained SDS
gel and cut in small pieces. In-gel tryptic digestion was carried
out as described (Shevchenko et al. 2006). Brieﬂy, the gel pieces
were washed (MeCN and NH4HCO3), reduced with DTT (10 mM
in NH4HCO3, 56 ◦C, 1 h), alkylated by iodoacetamide (55 mM
in NH4HCO3, rt, 30 min) and treated with trypsin (5 ng/l in
NH4HCO3) 37 ◦C. Tryptic digests were desalted and concentrated
using a micro C18 column (ZipTip, Millipore, MA). Peptides were
eluted from the C18 column with matrix (saturated solution of
-cyano-4-hydroxy-cinnamic acid in 50% H2O, 50% MeCN, 0.1%
TFA, 2–5 l) and directly deposited onto a steel target for analysis
by MALDI-TOF MS  (microﬂex LRF, Bruker Daltonics, MA). Spectra
were acquired in reﬂectron mode between m/z 500 and 4880. Raw
spectra were processed using BioTools (Bruker Daltonics, MA)  and
centred peptide masses exported to the MASCOT search engine
(Matrix Science, UK). Data were searched against the SwissProt
database and limited to human taxonomy, allowing CAM-cysteine
(carbamidomethylcysteine) as a ﬁxed and oxidised methionine
as a potential variable modiﬁcation. A peptide mass-tolerance of
150 ppm was  allowed.
Factor I processing of C3-conjugates
Factor I processing of C3-conjugates was  carried out as described
previously (Tsiftsoglou et al. 2005, 2006). Brieﬂy, C3 protein or
conjugate; C3(H2O), C3(NH2NH2) or C3(biotin–PEG4–hydrazide)
(2.75 g), was added to a mix  of fI (0.5 g) and fH (0.5 g) in reac-
tion buffer (10 mM potassium phosphate, 0.5 mM EDTA, pH 6.5)
with a ﬁnal reaction volume of 50 l. The reactions were incubated
at 37 ◦C, with shaking (1 h) and quenched (−80 ◦C). 5× SDS loading
buffer (10 l; 250 mM TrisHCL, 10% SDS, 30% glycerol, bromophenol
blue) containing DTT (40 mM)  was added and the samples boiled
prior to analysis by SDS-8.5% PAGE. Gel bands were visualised with
Coomassie blue R-250 stain.
Results
C3 thioester labelling and reaction temperature optimisation
The overall aim was  to detect whole, C3/-2M thioester proteins
on an SDS gel from a serum pull-down by targeting the chemi-
cal reactivity of the thioester bond with nucleophiles attached to a
reporter group (Biotin). This approach would use the same route
as causes the formation of C3(H2O) in the alternative pathway
(Figs. 1 and 2A). The chemoselective derivatization of the thioester
bond risked extensive processing of C3(N) by proteases, because
when the thioester bond reacts with the nucleophile the C3-
conjugate formed adopts a C3b-like structure that has binding sites
available for the serine proteases fI and fB (Nishida et al. 2006). The
products of C3(N) proteolysis would complicate the interpretation
of an SDS gel. Therefore, incubations with nucleophiles in serum
were performed at high NaCl concentration that acts to suppress
formation of C3(N)fB (Maeda and Nagasawa 1990) or C3(N)fHfI
(Soames and Sim 1997). However, overnight incubation of serum
with nucleophiles at room temperature and high NaCl resulted in
poor labelling and some degradation of C3 (data not shown). There-
fore the reaction was heated to increase the rate of reaction. A series
of reaction temperatures (all below 64 ◦C to prevent denaturation
(Sim and Sim 1981)) were chosen and monitored for thioester bond
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iotin–PEG4–hydrazide for 1 h at 52 ◦C. (A) Biotinylated proteins were detected by S
DS-PAGE showing total protein content detected by Coomassie staining.
eaction after 1 h. Puriﬁed C3 was incubated at high NaCl concentra-
ion in presence of biotin–PEG4–hydrazide (5 mM ﬁnal conc.) for 1 h
t different temperatures. The sample was then exhaustively dial-
sed to remove any excess biotin–PEG4–hydrazide that could coat
he SA-resin and cause poor pull-down. Puriﬁed C3 protein incu-
ated with biotin–PEG4–hydrazide was detected by Western blot
sing SA-HRP (Fig. 2B). Only traces of labelled C3 were observed at
7 ◦C and 42 ◦C. At 47 ◦C and 52 ◦C a clearly labelled single band of
3 corresponding to full size 188 kDa protein was observed, optimal
t 52 ◦C (Fig. 2B).
The experiment was repeated but with PEG-plasma (exclud-
ng only high molecular weight proteins) instead of puriﬁed C3
supporting material). The same temperature dependence was
bserved with PEG-plasma as for puriﬁed C3 (Fig. 2A). While the
eaction of biotin–PEG4–hydrazide with the thioester bond of C3
as barely detectable at 37 ◦C, labelling was optimal at 52 ◦C, 1 h.
o other C3 products were detected by Western blot in the PEG-
lasma so the conditions of high NaCl, 52 ◦C and 1 h incubation time
ere subsequently used throughout these studies.
abelled C3-conjugates are processed by factor I.
In serum, C3b is rapidly processed by fI preventing
urther C3 convertase (C3bBb) formation. Thioester bond-
unctionalized C3 (C3(N)) such as hydrolysed C3, C3(H2O) and
3(biotin–PEG4–hydrazide) possess C3b-like structure (Nishida
t al. 2006; Parkes et al. 1981). C3(N) displays binding sites for
H cofactor that allow further processing by fI initially to an
C3b-like molecule (iC3N in Fig. 2A). To test if the C3-conjugates
3(N) produced under these labelling conditions were behaving
imilarly to C3b and were not denatured, the C3(N) were tested for
I cleavage. C3 was reacted with biotin–PEG4–hydrazide, hydrazine
r hydrolysed at 52 ◦C for 1 h, in high NaCl buffer and dialysed
xhaustively before cleavage by fI in presence of fH (37 ◦C, 1 h).
he fragmentation pattern was analysed by SDS-PAGE. In the
bsence of fI and fH no cleavage products were observed and only
ntact - and -chain were detected (Fig. 2C). In the presencea. Blood, plasma, serum and PEG-plasma incubated with (+) or without (−)
P Western blot. Non-reducing (left panel) and reducing (right panel) conditions. (B)
of fI and fH, the -chain was almost completely processed and
the 41 kDa fragment was observed for all the C3(N) samples. The
other fragment formed, 72 kDa, co-ran with the -chain and so
was  not seen as a distinct product. As expected, the reference C3
protein (which was not subjected to labelling conditions) showed
no susceptibility to fI cleavage. Derivatized C3, C3(NH2NH2) and
C3(bio) was processed by fI. Under the same labelling conditions in
the absence of nucleophile, complete hydrolysis occurred, forming
C3(H2O), as judged by susceptibility to fI.
Comparison of chemical labelling of thioester proteins in blood,
sera, plasma or PEG-plasma
We were concerned that the different preparations of human
blood used could affect the assay. Therefore the optimized reaction
conditions were used for comparison of the reaction of the thioester
bond containing proteins in human blood, serum, plasma and PEG-
plasma. Biotin–PEG4–hydrazide was incubated with blood, serum,
plasma or PEG-plasma in high NaCl buffer for 1 h at 52 ◦C. The
reaction mixtures were analysed by SDS-PAGE and Western blot,
labelled proteins were detected by SA-HRP (Fig. 3). The Coomassie
stained gels reveal a large amount of total protein in all sam-
ples (Fig. 3B), the major-band on the non-reducing gel, is IgG
(∼150–160 kDa). On the reduced gel, the major band, present in
all the samples, is the -2M monomer, this is the most abundant
serum protein above 100 kDa on a reducing gel (∼180 kDa). The
Western blot suggested that at least two  proteins were speciﬁcally
labelled, and additionally some weaker bands of high molecular
weight were also detected (Fig. 3A). Under non-reducing condi-
tions (left panel) a protein corresponding to a dimer of -2M
can be seen clearly labelled for the blood and serum samples.
This -2M dimer of around 360 kDa is too big to resolve on this
gel. A protein corresponding to C3 in size is strongly labelled by
biotin–PEG4–hydrazide in all the samples. However C3, C3b, C4,
C4b and iC3b all run close together on a non-reducing gel so it
is not possible to distinguish between them or to know whether
they were processed further from residual protease, which appears
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(cheme 1. Procedure for labelling, pull-down and quantiﬁcation of thioester con-
aining proteins from blood, serum or plasma.
o be the case for the PEG-plasma sample. Under reducing con-
ition (right panel) the pattern clearly shows presence of -2M
onomer and C3 -chain (the C3 -chain containing the thioester
ond). This Western blot had poor resolution at lower molecu-
ar weights (Fig. 3A, right panel), a band less than 80 kDa was
abelled that could potentially be identiﬁed as the C371 frag-
ent. With improved separation the labelled band was shown to
ravel more than the 60 kDa-marker and could be either albumin
supporting material) or possibly C3b62 (Fig. 2A) the C3b -chain
ragment. The high-salt largely suppressed processing under the
onditions used, however there are bands that perhaps could be
he C372 fragment indicating residual protease activity, especially
n the blood and PEG-plasma samples. The pull-down from serum
Fig. 3A) showed good labelling of both C3 and -2M proteins. How-
ver, the plasma specimens showed little labelling of -2M, the
resence of anticoagulants may  interfere with labelling.
3 could be pulled-down from blood/plasma/serum/PEG plasma
A streptavidin pull-down assay was developed for
iotin–PEG4–hydrazide reacted samples to identify the labelled
roteins in blood, plasma and serum, as well as develop a direct
ethod for quantiﬁcation (Scheme 1). Biotinylated proteins were
ecovered by SA-resin, eluted with SDS-loading buffer and visu-
lized by SDS-PAGE and Coomassie stain (Fig. 4A). The efﬁciency
f the pull-down assay was tested by comparison of the samples
y Western blot (SA-HRP) before and after SA-resin pull-down
Fig. 4B). By Western blot almost all the biotinylated C3 wasy 217 (2012) 256– 264 261
pulled-down from blood and plasma and no residual labelled
proteins were detected after pull-down. Total protein in the C3
lane for two  C3(bio) samples before and after SA-pull-down were
compared by inspection of the stained C3 gel band on SDS-PAGE
(Fig. 4C). Only small quantities of protein were observed co-
running with the C3 band after SA-pull-down that may correspond
to C3(H2O), unlabelled C3 or unrecovered C3. This result indicated
that hydrolysis was  not a major competing reaction in the presence
of a good nucleophile as would be expected for a thioester (Yang
and Drueckhammer 2001). High molecular weight proteins were
pulled down in all the tested specimens: blood, plasma, serum and
PEG-plasma (Fig. 4A). In the absence of biotin–PEG4–hydrazide
there was  no non-speciﬁc binding. In addition, a low molecular
weight protein was  detected (visualized < 60 kDa-marker) identi-
ﬁed as albumin (supporting ﬁgure).  Five bands (i–v) (Fig. 4A) were
cut from the SDS gel, and the mass ﬁngerprint of each protein
recorded by tryptic digest and MALDI-TOF MS.  The three known
thioester containing proteins -2M, C4 and C3 were identiﬁed as
signiﬁcant matches (Fig. 4D). While C3 was detected readily in
blood, plasma, serum and PEG-plasma (in excision v) -2M (found
in three different forms, excision i-iii) was preferably detected in
serum. C4 was  identiﬁed in a weakly stained gel band (excision iv)
just above the major C3 band. C3 was  veriﬁed to very high scores
and the identiﬁed peptides clearly cover both C3 -and -chain
(Fig. 4E). The sequence coverage of the -2M and C4 proteins is
given in the supporting material.
Comparison of reactivity of thioester proteins with
biotin–PEG4–hydrazide vs biotin–PEG3–aminoxy
Although biotin–PEG4–hydrazide reacted well we considered
that using a stronger alpha effect nucleophile could optimize
labelling further and perhaps show some useful discrimination
of labelling between the thioester proteins. Biotin–PEG3–aminoxy
(Fig. 5A) and biotin–PEG4–hydrazide were incubated with PEG-
plasma and subjected to the SA-pull-down assay essentially as
described before (temperature 57 ◦C, ﬁnal probe concentration
1.8 mM)  (Scheme 1). Total protein before SA-pull-down and the
captured proteins were analysed by SDS-PAGE and visualized by
Coomassie staining (Fig. 5B). Surprisingly, although more nucle-
ophilic, the biotin–PEG3–aminoxy probe showed little reactivity
towards the C3 thioester, but it reacted with -2M. This suggests
that the biotin–PEG3–aminoxy probe may  be further developed as
an -2M selective probe. Differential reactivity of activated C3, C4A
and C4B for amine or oxygen nucleophiles has been observed pre-
viously, so the selectivity observed here may be under the same
sequence control (Law and Dodds 1997).
Measurement of active C3 in patient serum samples pre- and
post-surgery
To validate the C3 pull-down assay for quantitative mea-
surements, we deﬁned the linearity range within the applicable
concentration range. A 2-fold dilution series of a known concen-
tration of C3(bio) was  prepared and each sample subjected to
SA pull-down assay. The captured proteins were detected on gel
with Lumitein protein gel stain (which allows a linear range of
detection for at least 3 orders of magnitude) and the band inten-
sities were quantiﬁed (Fig. 6A). The dilution series clearly show
a linear response with good ﬁt. Complement activation is part of
the systemic inﬂammatory response. We  measured C3 levels pre
and post-operative as a system for testing the pull-down quan-
tiﬁcation assay. Plasma samples were taken from four patients
pre-surgery (POD0) and 48–60 h post-surgery (POD3). The sam-
ples were incubated with biotin–PEG4–hydrazide, dialysed and
subjected to the SA pull-down assay (Scheme 1). The gel band
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Fig. 4. Biotinylated protein pull-down. (A) Blood, plasma, serum and PEG-plasma were incubated with (+) or without (−) biotin–PEG4–hydrazide probe for 1 h at 52 ◦C.
Biotinylated proteins were captured by SA-resin, eluted by boiling the resin in SDS loading buffer and visualised by 6% SDS-PAGE and Coomassie staining. (B) Western blot
of  biotin–PEG4–hydrazide treated blood, plasma, serum and PEG-plasma pre (−) and post (+) SA capture. Biotinylated proteins detected by SA-HRP. (C) Total C3 protein in
reaction  mix pre (−) and post (+) SA capture. Two known amounts of C3(bio) were treated with SA-resin and the non-captured remaining protein detected by SDS-PAGE, with
lumeitin stain. (D) Table of identiﬁed peptides from pull-down experiment (A). Gel bands i–v were excised, and mass ﬁngerprint established by tryptic digest and MALDI-TOF
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bS,  searched against the Swissprot database by the Mascot search engine. All identi
core,  number of matched peptides and % sequence coverage. (E) Sequence coverage
ighlighted in grey, the GCGEQ (the internal thioester) is boxed, and the Ana (C3a) 
ntensities of the recovered C3 proteins were quantiﬁed and the
aired pre- (POD0) and post-operative samples (POD3) were plot-
ed side by side (Fig. 6B). As expected the inter-patient variation of
3 levels (POD0) was large. Moreover, all patients showed a lower
ctive C3 concentration post operation (POD3) compared to their
re-surgery values. The average C3 value decreased by 20% (Fig. 6B,
ight panel). The decrease in concentration of C3 between POD0 and
OD3 was statistically veriﬁed to the 10% level in a paired sample
-test. These results indicate an initial decrease in the level of active
3 as part of the post-operative inﬂammatory response. This pre-
iminary study shows potential for the use of chemical probes for
elective labelling of active C3 for quantiﬁcation.
ig. 5. Comparison of thioester protein functionalization for biotin–PEG4–hydrazide an
nd  biotin–PEG3–aminoxy (bottom). (B) PEG-plasma was  incubated with biotin–PEG4–hy
luted by boiling in SDS loading buffer and visualised by 6% SDS-PAGE and Coomassie sta
eside  the pull-down proteins (right three lanes).roteins (with scores greater than 56 and i.e., signiﬁcant (p < 0.05)) are listed with ID,
e identiﬁed C3 protein from excision v. -chain shown in italics, identiﬁed peptides
n underlined (cleaved during C3 activation by C3 convertase).
Discussion
The chemistry of peptide thioesters is increasingly familiar
because of their use as intermediates for chemical protein syn-
thesis (Dawson and Kent 2000). Peptide thioesters are generally
quite stable to hydrolysis at physiological pH and favour aminoly-
sis over hydrolysis (Yang and Drueckhammer 2001). The C3/-2M
thioester proteins all exist in plasma in an unactivated ‘native’
form, that resemble, in their chemical reactivity to nucleophiles,
peptide thioesters (Davies and Sim 1981). This resemblance was
what initially suggested the possibility of covalently attaching large
biomolecules to C3. In contrast, the exceptional reactivity of the
d biotin–PEG3–aminoxy. (A) Chemical structures of biotin–PEG4–hydrazide (top)
drazide, biotin–PEG3–aminoxy. Biotinylated proteins were captured with SA-resin,
ining. Total protein present in reaction mix  pre-SA capture (left 3 lanes) is shown
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Fig. 6. Quantitative detection of C3 in patient serum samples. (A) A linear correlation veriﬁed between C3 concentration and detected gel band intensity after SA pull-down
assay  and SDS-PAGE. Varying concentrations (2×dilution series) of puriﬁed C3(bio) were subjected to the SA-pull-down assay and the captured protein analysed by SDS-PAGE
and  Lumetein staining. Quantiﬁed gel band intensities plotted against C3 concentration and the linear trend line displayed. (B) Plasma samples from four surgical patients
(1–4)  undergoing elective joint replacement were tested for C3 levels before operation (POD0, unﬁlled bar) and 48–60 h after operation (POD3, ﬁlled bar). Four paired patient
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olasma  samples (POD0 and POD3) were incubated with biotin–PEG4–hydrazide an
ntensities (estimated C3 concentrations) were plotted against patient and conditio
aired  sample t-test to p = 0.09. The average change shown as normalised values of
hort-lived, activated form of the C3/-2M thioester proteins after
imited proteolysis probably reﬂects the increase in bond strain of
he helix spanning thioester during transition from a 310 helix in
he thioester domain of native C3 to an -helix (Fredslund et al.
006).
We have demonstrated that a single chemoselective chemi-
al reaction can be used to select and label a small group of
mmunoproteins from all the other proteins present in human
erum. This activity based assay can efﬁciently pull-down all the
iotinylated proteins in the sample and we have demonstrated
hat biotinylation of C3 was quantitative using optimised labelling
onditions. The use of high salt to inhibit processing and higher
emperature to shorten labelling time still gave the correctly folded
iotinylated products as demonstrated by fH and fI processing.
he presence of high salt suppresses post-processing of the con-
ugated thioester proteins so they can be detected whole (some
egradation was observed on incubation in PEG-plasma (Fig. 3)).
urthermore, the demonstration of a consistent drop in C3 con-
entration in human samples after elective surgery indicates that
his pull-down assay could potentially form the basis of a quan-
itative C3 assay. The importance of complement to the immune
esponse is reﬂected in the number of medical conditions cor-
elated with abnormal complement levels. For example, elevated
erum complement C3 confers risk for coronary heart disease and
ype 2 diabetes (Onat et al. 2005). The method described herein,
sing SDS-PAGE, although useful for demonstration and proof of
rinciple would not be suitable for running high numbers of clini-
al samples. However, it should be adaptable to an ELISA assay, for
xample capturing labelled C3 on plates coated with anti C3-Mab
nd quantifying with avidin–HRP or alternatively where the cap-
ure step is based on streptavidin binding and the development step
n antibodies raised against a range of C3/C4/-2M forms. With
he demonstration of efﬁcient ligation of labels to the thioester
roteins other potential applications can be envisaged. C3 (as C3b
nd C3d) is an excellent natural, non-toxic adjuvant (Cretin et al.
007; Villiers et al. 1999). Many efforts have been made to selec-
ively incorporate antigen to C3 or its processed derivatives. Using
irect conjugation at the thioester position under the optimised
onditions established it should now be possible to attach antigens
ovalently either directly or using bi-functional linkers. An advan-
age of this approach is that several copies of C3 can be attached in
 chemically deﬁned way to the antigen, allowing titration of the
ptimal adjuvant response. Additionally, ligation to non-proteinelled proteins were pulled-down and detected as in A. The quantiﬁed C3 gel band
 panel). The difference seen between POD0 and POD3 was statistically veriﬁed in a
ean POD0 and POD3 (right panel).
antigens such as carbohydrates, important targets of cancer, viral
and HIV vaccine development, can be explored (Astronomo and
Burton 2010). A similar approach of attaching imaging agents to C3
will help to further elucidate the complement pathway and observe
some of the cellular responses to C3.
In conclusion, we have developed a method to target thioester-
containing proteins and were able to capture and isolate full-length
C3, C4 and -2M from plasma. We  anticipate that this method
could be useful for screening and comparison of thioester proteins
from a wide variety of metazoans and most importantly to measure
the amounts of active C3, in different disease states. The reactivity
of the hydrazide moiety and other nucleophiles to thioesters may
also prove to be useful in the development of complement speciﬁc
inhibitors.
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